Tsuyoshi Takahashi1, Yuriko Terada1, Michael K Pasque1, Jingxia Liu2, Derek E Byers3, Chad A Witt3, Ruben G Nava1, Varun Puri1, Benjamin D Kozower1, Bryan F Meyers1, Daniel Kreisel1, G Alexander Patterson1, Ramsey R Hachem4. 1. Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO. 2. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO. 3. Division of Pulmonary & Critical Care, Department of Medicine, Washington University School of Medicine, St. Louis, MO. 4. Division of Pulmonary & Critical Care, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address: rhachem@wustl.edu.
Abstract
BACKGROUND: Combined pulmonary fibrosis and emphysema (CPFE) is recognized as a characteristic syndrome of smoking-related interstitial lung disease that has a worse prognosis than idiopathic pulmonary fibrosis (IPF). However, outcomes after lung transplantation for CPFE have not been reported. The aim of this study is to describe the clinical features and outcomes of CPFE after lung transplantation. RESEARCH QUESTION: What are the clinical features and outcomes of CPFE after lung transplantation? STUDY DESIGN AND METHODS: This is a single-center retrospective cohort study of patients with CPFE and IPF who underwent lung transplantation at our center between January 2011 and December 2016. We defined CPFE as ≥10% emphysema in the upper lung fields combined with fibrosis on high-resolution CT scan. We characterized the clinical features of patients with CPFE and compared their outcomes after lung transplantation with those with IPF. RESULTS: Twenty-seven of 172 (16%) patients with IPF met criteria for CPFE. Severe pulmonary hypertension was present in 16 of 27 (59%) patients with CPFE. On logistic regression analysis, CPFE was significantly associated with primary graft dysfunction (PGD) grade 3 (OR, 3.14; 95% CI, 1.18-8.37; P = .02). On competing risk regression analysis, CPFE was associated with acute cellular rejection (ACR) grade ≥ A2, and chronic lung allograft dysfunction (CLAD) (hazard ratio [HR], 1.89; 95% CI, 1.10-3.25; P = .02; HR, 1.96; 95% CI, 1.02-3.77; P = .04, respectively). Five-year survival was 79.0% for the CPFE group and 75.4% for the IPF group (log-rank P = .684). INTERPRETATION: After transplantation, patients with CPFE were more likely to develop PGD, ACR, and CLAD compared with those with IPF. However, survival was not significantly different between the two groups.
BACKGROUND: Combined pulmonary fibrosis and emphysema (CPFE) is recognized as a characteristic syndrome of smoking-related interstitial lung disease that has a worse prognosis than idiopathic pulmonary fibrosis (IPF). However, outcomes after lung transplantation for CPFE have not been reported. The aim of this study is to describe the clinical features and outcomes of CPFE after lung transplantation. RESEARCH QUESTION: What are the clinical features and outcomes of CPFE after lung transplantation? STUDY DESIGN AND METHODS: This is a single-center retrospective cohort study of patients with CPFE and IPF who underwent lung transplantation at our center between January 2011 and December 2016. We defined CPFE as ≥10% emphysema in the upper lung fields combined with fibrosis on high-resolution CT scan. We characterized the clinical features of patients with CPFE and compared their outcomes after lung transplantation with those with IPF. RESULTS: Twenty-seven of 172 (16%) patients with IPF met criteria for CPFE. Severe pulmonary hypertension was present in 16 of 27 (59%) patients with CPFE. On logistic regression analysis, CPFE was significantly associated with primary graft dysfunction (PGD) grade 3 (OR, 3.14; 95% CI, 1.18-8.37; P = .02). On competing risk regression analysis, CPFE was associated with acute cellular rejection (ACR) grade ≥ A2, and chronic lung allograft dysfunction (CLAD) (hazard ratio [HR], 1.89; 95% CI, 1.10-3.25; P = .02; HR, 1.96; 95% CI, 1.02-3.77; P = .04, respectively). Five-year survival was 79.0% for the CPFE group and 75.4% for the IPF group (log-rank P = .684). INTERPRETATION: After transplantation, patients with CPFE were more likely to develop PGD, ACR, and CLAD compared with those with IPF. However, survival was not significantly different between the two groups.
Authors: Allan R Glanville; Geert M Verleden; Jamie L Todd; Christian Benden; Fiorella Calabrese; Jens Gottlieb; Ramsey R Hachem; Deborah Levine; Federica Meloni; Scott M Palmer; Antonio Roman; Masaaki Sato; Lianne G Singer; Sofya Tokman; Stijn E Verleden; Jan von der Thüsen; Robin Vos; Gregory Snell Journal: J Heart Lung Transplant Date: 2019-04-03 Impact factor: 10.247
Authors: Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster Journal: Am J Respir Crit Care Med Date: 2006-06-29 Impact factor: 21.405
Authors: Adam Fang; Sean Studer; Steven M Kawut; Vivek N Ahya; James Lee; Keith Wille; Vibha Lama; Lorraine Ware; Jonathan Orens; Ann Weinacker; Scott M Palmer; Maria Crespo; David J Lederer; Clifford S Deutschman; Benjamin A Kohl; Scarlett Bellamy; Ejigayehu Demissie; Jason D Christie Journal: Chest Date: 2010-09-23 Impact factor: 9.410
Authors: K Bando; R J Keenan; I L Paradis; H Konishi; K Komatsu; R L Hardesty; B P Griffith Journal: Ann Thorac Surg Date: 1994-11 Impact factor: 4.330
Authors: Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson Journal: Am J Respir Crit Care Med Date: 2018-09-01 Impact factor: 21.405
Authors: Akinori Hata; Takuya Hino; Rachel K Putman; Masahiro Yanagawa; Tomoyuki Hida; Aravind A Menon; Osamu Honda; Yoshitake Yamada; Mizuki Nishino; Tetsuro Araki; Vladimir I Valtchinov; Masahiro Jinzaki; Hiroshi Honda; Kousei Ishigami; Takeshi Johkoh; Noriyuki Tomiyama; David C Christiani; David A Lynch; Raúl San José Estépar; George R Washko; Michael H Cho; Edwin K Silverman; Gary M Hunninghake; Hiroto Hatabu Journal: Radiology Date: 2022-05-31 Impact factor: 29.146